01/24/23 6:00 AMNasdaq : MNKD conferencesMannKind Corporation to Participate in the Lytham Partners Investor Select ConferenceMannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that itsRHEA-AIneutral
01/23/23 6:05 AMNasdaq : MNKD clinical trialMannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung DiseaseDirect delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on clofazimine inhalation suspension demonstrates promising tolerability andRHEA-AIneutral
01/05/23 6:00 AMNasdaq : MNKD conferencesMannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its ChiefRHEA-AIneutral
11/10/22 6:05 AMNasdaq : MNKD conferencesMannKind to Present Two Posters at 22nd Annual Diabetes Technology MeetingTechnosphere ® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to beRHEA-AIneutral
11/08/22 8:00 AMNasdaq : MNKD earningsMannKind Corporation Reports 2022 Third Quarter Financial ResultsConference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 million 3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBERHEA-AIneutral
11/01/22 6:00 AMNasdaq : MNKD earningsMannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AMRHEA-AIneutral
09/21/22 5:00 PMNasdaq : MNKD conferencesMannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor ConferenceMannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its ChiefRHEA-AIneutral
09/06/22 6:15 AMNasdaq : MNKD clinical trialMannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBERHEA-AIneutral
09/01/22 6:00 AMNasdaq : MNKD conferencesMannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceMannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its ChiefRHEA-AIneutral
08/09/22 4:00 PMNasdaq : MNKD earningsMannKind Corporation Reports 2022 Second Quarter Financial ResultsConference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere ® inhalation platform V-Go ® acquired May 31; $2.1 million Net Revenue recognized for June 2Q 2022 Commercial Products Net Revenue of $12.7RHEA-AIneutral